^
Association details:
| Biomarker: | TIGIT expression |
|---|---|
| Cancer: | Esophageal Squamous Cell Carcinoma |
| Drug: | Tevimbra (tislelizumab) (PD1 inhibitor) + ociperlimab (BGB-A1217) (TIGIT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1533P - Advantig-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (CT) in patients (pts) with metastatic oesophageal squamous cell carcinoma (ESCC) and oesophageal adenocarcinoma (EAC)
Published date:
10/16/2023
Excerpt:
Treatment-naïve adult pts with histologically/cytologically confirmed metastatic ESCC (C6) or EAC (C7) were enrolled. Pts received the RP2D of OCI + TIS with cisplatin + 5-fluorouracil/paclitaxel until disease progression, intolerable toxicity, or consent withdrawal....ORRs by biomarker subgroups: C6, 100% in pts with PD-L1 tumor area positivity (TAP) score ≥10% (n=4) vs 76.9% in pts with PD-L1 TAP <10% (n=13); 80.0% in pts with TIGIT IC score ≥5% (n=10) vs 87.5% in pts with TIGIT IC <5% (n=8).
Secondary therapy:
cisplatin; 5-fluorouracil; paclitaxel
Trial ID:
